LPL Financial
ANTH

LPL Financial’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

LPL Financial’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,262
Closed -$221K – 2942
2015
Q2 		$221K Buy
+3,262
New +$151K ﹤0.01% 2554

Other funds holding ANTH

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

LPL Financial's ANTH Position: Q3 2015 in Review

LPL Financial sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2015, closing a stake of 3,262 shares — an estimated $221K sold.

LPL Financial first reported a position in ANTH in Q2 2015 and held it in 1 quarter. The position peaked at $221K in Q2 2015. 86 funds tracked by Wall St. Rank hold ANTH as of Q3 2015.

  • LPL Financial reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • LPL Financial sold 3,262 Anthera Pharmaceuticals, Inc. shares in Q3 2015, an estimated $221K.
  • LPL Financial first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • LPL Financial's Anthera Pharmaceuticals, Inc. position peaked at $221K in Q2 2015.
  • 86 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2015.

Based on LPL Financial's 13F filing for Q3 2015, filed 13 Nov 2015.